Influenza Vaccine

Number: 0035

Policy

Aetna considers standard or preservative-free trivalent or quadrivalent injectable influenza vaccines medically necessary according to the recommendations of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

Aetna considers intranasally administered influenza vaccine medically necessary for members aged 2 through 49 years old. 

For additional influenza vaccine information, including but not limited to contraindications, please see the Background section.

See also CPB 0476 - Influenza Rapid Diagnostic Tests.

Background

Influezna ("the flu") is a contagious respiratory illness caused by viruses that infect the nose, throat, and sometimes the lungs. Influenza can cause mild to severe illness, and at times can lead to death. Symptoms, which may appear suddenly, include fever, chills, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, and fatigue. It is important to note that not everyone with the flu will have a fever. In addition, some people may have vomiting and diarrhea, though this is more common in children than adults. Most experts believe that flu viruses spread mainly by tiny droplets made when people infected with the flu cough, sneeze or talk. Less often, a person might get the flu from contact with a contaminated surface or object and subsequently touch their own mouth, nose, or possibly their eyes. Thus, the Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP), recommends individuals to get a flu vaccine each year in order to prevent contracting and spreading influenza viruses (CDC, 2019).

The Influenza virus vaccine imparts immunity against the influenza virus by stimulating production of antibodies that are specific to the disease. Persons who receive the vaccine will be immune only to those strains of the virus from which the vaccine was prepared. Influenza viruses are recognized by the surface antigens they carry, and two such antigens, hemagglutinin (H) and neuraminidase (N) have been identified and are used to classify the various viruses. Subtypes of these strains (H1, H2, H3, N1, N2) are associated with influenza A virus and have been recognized to cause disease in humans. Immunity to these surface antigens increases resistance to infection and decreases the severity of the disease if infection occurs. Eventually, antigenic variation can occur, and immunity to one strain may no longer impart immunity to distantly related subtypes of the virus. Influenza B viruses also exhibit antigenic variation, and new variants of both types of viruses continue to cause widespread epidemics of respiratory disease.

Influenza virus vaccine is available as: Afluria Quadrivalent, Fluad Quadrivalent, Fluarix Quadrivalent, Flublok Quadrivalent, Flucelvax Quadrivalent, FluLaval Quadrivalent, FluMist Quadrivalent, Fluzone High-Dose, and Fluzone Quadrivalent.

Contraindications may include:

• Severe allergic reaction (anaphylaxis) to any component of the vaccine, including egg protein, or to a previous dose of any influenza vaccine.
• Concomitant aspirin therapy in children and adolescents (FluMist only).

The following warnings and precautions should be taken into account prior to administration of the influenza vaccine:

• Guillain‐Barré Syndrome – If Guillain‐Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give influenza vaccine should be based on careful consideration of the potential benefits and risks.
• Altered Immunocompetence – Immunocompromised persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained.
• Latex Allergy – The prefilled syringe tip caps for Fluarix, Fluvirin, Fluzone, and Fluzone high dose, contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals.
• Wheezing – In clinical trials, risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FluMist. Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FluMist.

Common side effects for the flu shot may include mild fever, body aches, and fatigue for a few days after the vaccine, and soreness at the injection site.

It takes 1 to 2 weeks after receiving the vaccination for protective antibodies to form.  Influenza vaccines are 70 to 90 % effective in preventing influenza among healthy adults.  Among elderly persons or people with chronic conditions, the vaccine may be less effective in preventing disease than in preventing serious complications and death.

Influenza virus infection is so common that the number of people infected each season can only be estimated. A paper published in Clinical Infectious Diseases on "Seasonal Incidence of Symptomatic Influenza in the United States" (Tokars et al, 2018) found that between 3% and 11% of the U.S. population gets infected and develops flu symptoms each year. The 3% estimate is from the 2011-2012 season, which was an H1N1-predominant season classified as being of low severity. The estimated incidence of flu illness during two seasons was around 11%; 2012-2013 was an H3N2-predominant season classified as being of moderate severity, while 2014-2015 was an H3N2 predominant season classified as being of high severity. The authors also found that children younger than 18 are more than twice as likely to develop a symptomatic flu infection than adults 65 and older (CDC, 2019).

Both symptomatic and asymptomatic individuals are able to spread influenza to others. People are most contagious in the first 3-4 days after their illness begins. Some otherwise healthy adults may be able to infect others beginning 1 day before symptoms develop and up to 5 to 7 days after becoming sick. Some people, especially young children and those with weakened immune systems, might be able to infect others for an even longer time. The onset of symptoms from the time of exposure and infection to when symptoms begin is about 2 days, but can range from about 1 to 4 days. The influenza vaccine has been shown to reduce flu related illnesses and the risk of serious flu complications that can result in hospitalization or even death. The CDC also recommends everyday preventive actions (like staying away from people who are sick, covering coughs and sneezes and frequent handwashing) to help slow the spread of germs that cause respiratory (nose, throat, and lungs) illnesses, like flu (CDC, 2019).

Seasonality

According to the CDC, seasonal influenza (flu) viruses are detected year-round in the United States; however, are most common during the fall and winter. The exact timing and duration of flu seasons can vary, but influenza activity often begins to increase in October. Most of the time flu activity peaks between December and February, although activity can last as late as May (CDC, 2018).

During the 2021–2022 influenza season, the following types of vaccines are expected to be available: inactivated influenza vaccines (IIV4s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4). Recommendations from the Advisory Committee on Immunization Practices (ACIP) for the 2021-2022 influenza season include the following (note, no preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended, and appropriate product is available):

• Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications;
• Health care personnel, caregivers and persons who live with those who are at increased risk for medical complications attributed to severe influenza;
• Balancing considerations regarding the unpredictability of timing of onset of the influenza season and concerns that vaccine-induced immunity might wane over the course of a season, it is recommended that vaccination should be ideally administered by the end of October, but should continue to be offered as long as influenza viruses are circulating locally and unexpired vaccine is available;
• Children aged 6 months through 8 years who require 2 doses should receive their first dose as soon as possible after the vaccine becomes available to allow the second dose (which must be administered ≥4 weeks later) to be received by the end of October;
• Persons who are pregnant or who might be pregnant during the influenza season should receive influenza vaccine;
• Vaccination soon after vaccine is available may also be considered for pregnant persons in their third trimester;
• For non-pregnant adults, vaccination in July and August should be avoided, even if vaccine is available during these months, unless there is concern that later vaccination might not be possible;
• If vaccine supply is limited, see priority groups for vaccination (below).

Per the Advisory Committee on Immunization Practices (ACIP), vaccination to prevent influenza is particularly important for persons who are at increased risk for severe illness and complications from influenza and for influenza-related outpatient, emergency department, or hospital visits. When vaccine supply is limited, vaccination efforts should focus on delivering vaccination to persons at higher risk for medical complications attributable to severe influenza who do not have contraindications. These persons include (no hierarchy is implied by order of listing):

• All children aged 6 through 59 months;
• All persons aged 50 years and older;
• Adults and children who have chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus);
• Persons who are immunocompromised due to any cause (including but not limited to immunosuppression caused by medications or HIV infection);
• Women who are or will be pregnant during the influenza season;
• Children and adolescents (aged 6 months through 18 years) who are receiving aspirin- or salicylate-containing medications and who might be at risk for experiencing Reye syndrome after influenza virus infection;
• Residents of nursing homes and other long-term care facilities;
• American Indians/Alaska Natives; and
• Persons who are extremely obese (body mass index ≥40 for adults).

The 2021–2022 influenza season is expected to coincide with continued circulation of SARS-CoV-2, the virus that causes COVID-19. Influenza vaccination of persons aged 6 months and older to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19.

ACIP (2021) recommendations for vaccination of persons with COVID-19:

• Persons in isolation for COVID-19 or in quarantine for known or suspected exposures should not be vaccinated if vaccination will pose an exposure risk to others in the vaccination setting; 
• For persons who are moderately or severely ill, vaccination should be deferred until they have recovered. Moderate or severe acute illness with or without fever is a general precaution to vaccination;
• Persons who are mildly ill may be vaccinated; alternatively, vaccination may be deferred until recovery to avoid confusing COVID-19 illness symptoms with post-vaccination reactions.

Intranasal Vaccine / Live Attenuated Influenza Vaccine (LAIV3, LAIV4)

On June 17, 2003, the FDA approved FluMist (manufactured by MedImmune, LLC), an intranasally administered trivalent live attenuated influenza vaccine (LAIV3), for the prevention of influenza disease caused by Influenza A subtype viruses and the type B virus contained in the vaccine. The nasal-spray influenza vaccine is a made from a cold-adapted live attenuated virus that is sprayed as an aerosol from a syringe into both nostrils.  The FDA originally approved the nasal-spray influenza vaccine only for healthy people ages 5 to 49 years of age, a group for whom influenza vaccination is considered elective.  On September 19, 2007, the FDA approved expanding the population for use of the nasal influenza vaccine FluMist to include children between the ages of 2 and 5 years based, in part, on its evaluation of randomized, controlled clinical trials demonstrating the efficacy of FluMist in the prevention of virus culture-confirmed influenza illness. In clinical trials, risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FluMist (LAIV3).

On February 29, 2012, FDA approved FluMist Quadrivalent (LAIV4), a formulation containing two Influenza A subtype viruses and two type B viruses for use in persons 2 through 49 years of age. The effectiveness of FluMist Quadrivalent was based on an evaluation of immune responses in vaccinated persons, as well as the demonstrated effectiveness of the trivalent formulation. During the 2016–17 and 2017–18 influenza seasons, the Advisory Committee on Immunization Practices (ACIP) recommended that LAIV4 not be used because of concerns about low effectiveness against influenza A (H1N1) pdm09-like viruses circulating in the United States during the 2013–14 and 2015–16 seasons. Data from the U.S. Influenza Vaccine Effectiveness Network for the 2015-2016 season showed the estimate for LAIV VE among study participants in that age group against any flu virus was 3 percent (with a 95 percent Confidence Interval (CI) of -49 percent to 37 percent). This 3 percent estimate means no protective benefit could be measured. In comparison, IIV (flu shots) had a VE estimate of 63 percent (with a 95 percent CI of 52 percent to 72 percent) against any flu virus among children 2 years through 17 years. The data from 2015-2016 follows two previous seasons (2013-2014 and 2014-2015) showing poor and/or lower than expected vaccine effectiveness (VE) for LAIV. For the 2017–18 season, a new influenza A(H1N1)pdm09-like virus (A/Slovenia/2903/2015) was included in LAIV4, replacing A/Bolivia/559/2013. However, LAIV4 was not recommended for use in the United States during 2017–18, and no U.S. effectiveness estimates were available.

In a systematic review, Prutsky and colleagues (2014) evaluated the evidence on LAIV in children younger than 2 years.  These investigators searched Medline, EMBASE, the Cochrane Library, Web of Science, Scopus, PsycInfo and CINAHL through February 2013 for existing systematic reviews, randomized controlled trials (RCTs) and observational studies (for safety).  They included studies enrolling healthy children less than 2 years of age who received LAIV, compared with placebo or IIV.  Data were extracted independently by 2 investigators.  The relative risk (RR) was pooled across studies using the random effects model.  These researchers found 7 eligible RCTs and 2 observational studies.  Randomized controlled trials included 6,281 children and were at low-to-moderate risk of bias.  Live attenuated influenza vaccine reduced the incidence of influenza compared with placebo (RR = 0.36, 95 % CI: 0.23 to 0.58, p < 0.05) with a number needed to vaccinate of 17.  Live attenuated influenza vaccine increased the incidence of minor side effects (fever and rhinorrhea); it had a similar effect in preventing influenza (RR = 0.76, 95 % CI: 0.45 to 1.30, p > 0.05) compared with IIV.  There was an increase of hospitalization rate (post-hoc analysis) and medical attended wheezing with LAIV.  The authors concluded that LAIV is highly effective in children less than 2 years of age compared with placebo and is as effective to IIV.  The safety profile of LAIV is reasonable although evidence is sparse.  They stated that LAIV may be considered as an option in this age group particularly during seasons with vaccine shortage.

In February 2018, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of a renewed recommendation for the use of FluMist Quadrivalent for the prevention of influenza for the 2018-19 season. Flumist Quadrivalent , intranasal spray, continues to be available for prevention of influenza for the 2019-2020 season for ages 2 to 49 years of age (MedImmune, 2019).

Administration of vaccine via aerosol avoids local soreness from injection.  Nasal-spray influenza vaccine, however, is derived from a live attenuated virus and is associated with an increased incidence of upper respiratory symptoms (sore throat, rhinitis) following administration. The most common side effects seen with administration of the FluMist intranasal vaccine include: runny nose or nasal congestion, sore throat, and fever. (MedImmune, 2019).

Certain individuals should not receive the nasal spray flu vaccine including:

• Children younger than two years of age and adults older than 50
• Pregnant women and nursing mothers
• People with a medical condition that places them at higher risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airways disease; people with medical conditions such as diabetes or kidney failure; or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system.
• Any patient with asthma
• Children 2‐4 years of age who had wheezing in the past 12 months. Children or adolescents 2 through 17 years of age currently taking aspirin or aspirin containing medication. Children or adolescents should not be given aspirin for 4 weeks after getting FluMist or FluMist Quadrivalent unless your healthcare provider tells you otherwise.
• Patients who have had Guillain‐Barré syndrome (GBS), a rare disorder of the nervous system, with any prior influenza vaccinations.
• People who have a severe allergy to egg proteins, chicken proteins, gentamicin, gelatin, arginine, or who are allergic to any of the nasal spray vaccine components.

Inactivated Influenza Vaccines (IIV3, IIV4)

In 2012, the US Food and Drug Administration approved quadrivalent formulation of the inactivated influenza vaccine, which contains two strains of influenza A virus and two strains of influenza B virus (Hibberd, 2012). Fluarix Quadrivalent is a preservative-free vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It was initially approved for use in persons 3 years of age and older. (FDA, 2013). Fluarix Quadrivalent has now been approved for use in persons aged 6 months and older (GSK, 2020).

A high dose seasonal influenza vaccine specifically intended for people aged 65 and older was approved by the FDA on December 23, 2009.  Fluzone High-Dose (Sanofi Pasteur Inc.) was approved via the FDA's accelerated approval pathway.  It contains 4 times the total amount of virus hemagglutinin (180 mcg) found in other seasonal vaccines.  The higher-dose formulation is based on the theory that immune functions weaken with age and that the elderly are especially vulnerable to complications from seasonal influenza.  In clinical studies, Fluzone High-Dose demonstrated an enhanced immune response compared with Fluzone in individuals aged 65 and older.  Common side effects were more frequent with the high-dose than with regular-dose formulations, but the rate of serious adverse events was no higher.  Since the product received accelerated approval, the manufacturer must conduct further studies to verify the higher efficacy of the vaccine among older people (FDA, 2009). The Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) have not expressed a preference for any flu vaccine indicated for people 65 and older. Data from studies comparing the efficacy or effectiveness of HD-IIV3, aIIV3, and RIV4 directly with one another against laboratory-confirmed influenza outcomes among older adults are limited, which prevents recommending one of these three vaccines over another for this population. Thus, for persons aged 65 years and older, any age-appropriate IIV formulation (standard dose or high dose, trivalent or quadrivalent, unadjuvanted or adjuvanted) or RIV4 are acceptable options (CDC, 2019).

Fluzone Quadrivalent received FDA approval on June 7, 2013.  Fluzone received approval for active immunization of persons 6 months of age and older for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine (FDA, 2013c).

An egg-free influenza vaccine option is Flucelvax Quadrivalent. Flucelvax Quadrivalent (Seqirus Inc.) is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Flucelvax is approved for use in persons 4 years of age and older; for intramuscular use only. Flucelvax includes cell-based manufacturing, an alternative production process to traditional egg-based manufacturing. Thus, contains no egg protein or antibiotics. Flucelvax Quadrivalent is available as a pre-filled syringe, which contains no preservative. It is also available in mutli-dose vials which does contain thimerosal, a mercury derivative added as a preservative (Seqirus, 2019).

Fluad, initially approved by the U.S. FDA in 2015, was formulated for the 2020-2021 influenza season as a  trivalent, inactivated influenza vaccine, adjuvanted, intramuscular injection for persons 65 years of age and older. Fluad is prepared from virus propagated in the allantoic cavity of embryonated hens’ eggs inoculated with a specific type of influenza virus. The most common (10% or more) local (injection site) adverse reactions observed in clinical studies were injection site pain (25%) and tenderness (21%). The most common (10% or more) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%) and fatigue (13%) (Seqirus, 2020). 

In 2020, the U.S. FDA approved Fluad Quadrivalent, adjuvanted influenza vaccine, for persons 65 years and older. Fluad Quadrivalent for the 2021-2022 influenza season is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by virus subtypes A and B contained in the vaccine. The indication for persons 65 years and older is approved under accelerated approval based on the immune response elicited by Fluad Quadrivalent. Continued approval for this indication may be contigent upon verifcation and description of clinical benefit in a confirmatory trial (Seqirus, 2021).

Per ACIP (2021), the approved age indication for the cell culture–based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), has been expanded from ages ≥4 years to ages ≥2 years.

Recombinant Influenza Vaccine (RIV3, RIV4)

On January 16, 2013 the FDA approved Flublok in individuals aged 18 through 49 for active immunization against disease caused by influenza virus. Flublok was the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok's manufacturing technology allowed for production of large quantities of the influenza virus protein, hemagglutinin (HA), the active ingredient in all inactivated influenza vaccines that is essential for entry of the virus into cells of the body. Flublok contains three, full-length, recombinant HA proteins to help protect against two influenza virus A strains, H1N1 and H3N2, and one influenza virus B strain (FDA, 2013). 

In a June 19-20, 2013 meeting, ACIP voted and unanimously approved language changes to the vaccine safety update to state that "for individuals who have no known history of exposure to egg but who are suspected of being egg-allergic on the basis of previously performed allergy testing, use of RIV3 or consultation with a physician with expertise in the management of allergic conditions should be obtained prior to vaccination.  If the patient only experiences hives after ingestion of egg, administer RIV3 (FluBlok) if the patient is aged 18 to 49 years or administer a inactivated influenza vaccine (IIV) of choice and observe for at least 30 minutes following vaccination.  If more severe reactions have been noted with eggs administer RIV3 (FluBlok) or refer to a clinician with expertise in allergic reaction" (Lardy et al, 2013).

As of 2019, Flublok was available as Flublok Quadrivalent, a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses. Flublok Quadrivalent is approved for use in persons 18 years of age and older. Flublok Quadrivalent contains recombinant HA proteins of the four strains of influenza virus specified by the heatlh authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hemagglutination inhibition (HI) antibody. Flublok Quadrivalent contains no egg proteins, antibiotics, or preservatives. The single-dose, pre-filled syringes contain no natural rubber latex (Sanofi Pasteur, 2019).

Intradermal Vaccine

On May 11, 2011, the FDA approved Sanofi Pasteur's supplemental Biologics License Application for licensure of Fluzone Intradermal (Influenza Virus Vaccine).  Fluzone intradermal vaccine is indicated for active immunization of adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. The most common side effects observed with the administration of Fluzone Intradermal vaccine include injection‐site reactions, erythema, induration, swelling, pain, and pruritus. Erythema, induration, swelling, and pruritus occurred more frequently following Fluzone Intradermal than Fluzone. However, Sanofi Pasteur, the manufacturer of standard dose Intradermal IIV4, discontinued the production and supply of Fluzone Intradermal Quadrivalent vaccine at the conclusion of the 2017-2018 influenza season (MDedge, 2018).

Frenck and colleagues (2011) examined if reduced doses of trivalent inactivated influenza vaccine (TIV) administered by the intradermal (ID) route generated similar immune responses to standard TIV given intramuscularly (IM) with comparable safety profiles.  Recent changes in immunization recommendations have increased the number of people for whom influenza vaccination is recommended.  Thus, given this increased need and intermittent vaccine shortages, means to rapidly expand the vaccine supply are needed.  Previously healthy subjects 18 to 64 years of age were randomly assigned to 1 of 4 TIV vaccine groups: standard 15 μg HA/strain TIV IM, either 9 μg or 6 μg HA/strain of TIV ID given using a new microinjection system (BD Soluvia™ Microinjection System(1)), or 3 μg HA/strain of TIV ID given by Mantoux technique.  All vaccines contained A/New Caledonia (H1N1), A/Wyoming (H3N2) and B/Jiangsu strains of influenza.  Sera were obtained 21 days after vaccination and hemagglutination inhibition (HAI) assays were performed and geometric mean titers (GMT) were compared among the groups.  Subjects were queried immediately following vaccination regarding injection pain and quality of the experience.  Local and systemic reactions were collected for 7 days following vaccination and compared.  A total of 10 study sites enrolled 1,592 subjects stratified by age; 18 to 49 years (n = 814) and 50 to 64 years (n = 778).  Among all subjects, for each of the 3 vaccine strains, the GMTs at 21 days post-vaccination for both the 9 μg and the 6 μg doses of each strain given ID were non- inferior to GMTs generated after standard 15 μg doses/strain IM.  However, for the 3 μg ID dose, only the A/Wyoming antigen produced a GMT that was non-inferior to the standard IM dose.  Additionally, in the subgroup of subjects 50 to 64 years of age, the 6 μg dose given ID induced GMTs that were inferior to the standard IM TIV for the A/H1N1 and B strains.  No ID dose produced a GMT superior to that seen after standard IM TIV.  Local erythema and swelling were significantly more common in the ID groups but the reactions were mild-to-moderate and short-lived.  No significant safety issues related to intradermal administration were identified.  Participants given TIV ID provided favorable responses to questions about their experiences with ID administration.  The authors concluded that for the aggregated cohorts of adults 18 to 64 years of age, reduced doses (6 μg and 9 μg) of TIV delivered ID using a novel microinjection system stimulated comparable HAI antibody responses to standard TIV given IM.  The reduced 3 μg dose administered ID by needle and syringe, as well as the 6 μg ID for subjects aged 50 to 64 years of age generated poorer immune responses as compared to the 15 μg IM dose.

Pileggi et al (2015) stated that the primary influenza prevention strategy is focused on annual vaccination according to the categories identified in the various countries as being at greatest risk of complications.  Many studies were conducted in order to demonstrate that ID vaccine formulation represents a promising alternative to conventional IM formulation, especially in subjects with an impaired immune system.  However, there is no consensus whether the safety and effectiveness of ID is equivalent to IM in these subjects.  Therefore, these investigators performed a meta-analysis of RCTs to compare the immunogenicity and safety of ID and IM influenza vaccines in subjects with a depleted immune system.  These researchers conducted a search strategy of medical literature published until November 2014 in order to identify RCTs that evaluated the immunogenicity and safety of ID compared with IM influenza vaccines in immuno-compromised patients.  They identified a total of 269 citations through research in electronic databases and scanning reference lists.  Of these, 6 articles were included in the meta-analysis, for a total of 673 subjects.  The sero-protection rate induced by the ID vaccine is comparable to that elicited by the IM vaccine.  The overall RR was 1.00 (95 % CI: 0.91 to 1.10) for A/H1N1 strain, 1.00 (95 % CI: 0.90 to 1.12) for A/H3N2 and 0.99 (95 % CI: 0.84 to 1.16) for B strain.  No significant differences in the occurrence of systemic reactions were detected (17.7 % in the ID group versus 18.2 % in the IM group) with a pooled RR = 1.00 (95 % CI: 0.67 to 1.51), whereas ID administration caused significantly more injection site reactions with a mean frequency of 46 % in the ID group compared to 22 % in the IM group, with a pooled RR = 1.89 (95 % CI: 1.40 to 2.57).  The authors concluded that ID influenza vaccine had shown a similar immunogenicity and safety to the IM influenza vaccine in immuno-compromised patients, and it may be a valid option to increase compliance to influenza vaccination in these populations.

Booster Dose of Influenza Vaccine

Liao and colleagues (2016) noted that booster influenza vaccination has been recommended for patients with chronic renal disease in order to enhance the immune response to the influenza vaccine; however, the effectiveness of a booster influenza vaccination is a matter of controversy.  These investigators performed a meta-analysis to determine the effectiveness in patients with hemodialysis (HD), peritoneal dialysis (PD) and renal transplant recipient (RT).  The sero-protection rate was used as a serologic parameter to describe the immune response to the vaccine.  Statistical analysis was performed to calculate the pooled rate difference (RD) and 95 % CI.  The pooled RD for the H1N1, H3N2 and B influenza vaccines was 0.02 (95 % CI: -0.02 to 0.06), 0.05 (95 % CI: -0.01 to 0.11), 0.04 (95 % CI: -0.02 to 0.10), respectively.  The authors concluded that a booster dose of the influenza vaccine did not effectively enhance immunogenicity.  Therefore, a booster dose of vaccine is not recommended for patients with hemodialysis, peritoneal dialysis and renal transplant recipients.

Egg Allergy

Egg allergy may be confirmed by a consistent medical history of adverse reactions to eggs and egg-containing foods, plus a skin and/or blood testing for IgE antibodies to egg proteins.

There are now influenza vaccine options for persons with an egg allergy.

Per ACIP (2021), most available influenza vaccines, with the exceptions of RIV4 (Flublok Quadrivalent) and ccIIV4 (Flucelvax Quadrivalent), are prepared by propagation of virus in embryonated eggs and might contain trace amounts of egg proteins, such as ovalbumin. For persons who report a history of egg allergy, ACIP recommends the following:  

• Persons with a history of egg allergy who have experienced only urticaria (hives) after exposure to egg should receive influenza vaccine. Any licensed, recommended influenza vaccine (i.e., any IIV4, RIV4, or LAIV4) that is otherwise appropriate for the recipient’s age and health status can be used.
• Persons who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or recurrent vomiting) or who required epinephrine or another emergency medical intervention can similarly receive any licensed, recommended influenza vaccine (i.e., any IIV4, RIV4, or LAIV4) that is otherwise appropriate for their age and health status. If a vaccine other than ccIIV4 or RIV4 is used, the selected vaccine should be administered in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices). Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic reactions.

No postvaccination observation period is recommended specifically for egg-allergic persons. However, ACIP recommends that vaccine providers consider observing patients (seated or supine) for 15 minutes after administration of any vaccine to decrease the risk for injury should syncope occur.

Vaccine Preservatives

Some researchers have raised concern over the preservative added to vaccines, such as thimerosal which contains mercury. Thimerosal prevents the growth of microbes and containation in the multi-dose vial when individual doses are drawn from it. Receiving a vaccine contaminated with bacteria can be deadly. However, there were public concerns on the risk of thimerosal to children and the possible link to autism. Although standard thimerosal-preserved influenza vaccines contain trace amounts of mercury, the American Academy of Pediatrics, the American Academy of Family Physicians, the Advisory Committee on Immunization Practices and the U.S. Public Health Service had issued a joint statement advising the removal of thimerosal-containing vaccines from vaccines routinely recommended for infants (AAP, 2000; CDC, 2015). The joint statement explains that "[w]hile there was no evidence of any harm caused by low levels of thimerosal in vaccines and the risk was only theoretical, this goal was established as a precautionary measure.  There is public concern about the health effects of mercury exposure of any sort, and the elimination of mercury from vaccines was judged a feasible means of reducing an infant’s total exposure to mercury in a world where other environmental sources of exposure are more difficult or impossible to eliminate (e.g., certain foods)."  Other persons who are sensitive to thimerosal should avoid vaccines containing this preservative.  Furthermore, the U.S. Public Health Service recommended efforts be made to eliminate or reduce the thimerosal content in vaccines as part of an over-all strategy to reduce mercury exposures from all sources and ACIP and other federal agencies and professional medical organizations continue to support efforts to provide thimerosal preservative-free vaccine options (ACIP, 2008).

There has been no evidence of harm caused by low doses of thimerosal in vaccines, except for minor reactions like redness and swelling at the injection site (CDC, 2015). Nonetheless, except for some flu vaccines in multi-dose vials, no recommended childhood vaccines contain thimerosal as a preservative (CDC, 2013). There are single-dose influenza vaccines on the market that do not contain thimerosal (e.g., Fluzone Quadrivalent, (Sanofi Pasteur Inc); Afluria Quadrivalent, (Seqirus Inc); Fluarix Quadrivalent, Flulaval Quadrivalent (GSK).

The American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Family Physicians (AAFP) recommend routine vaccination of all pregnant women. Although some researchers have raised concerns that thimerosal, a mercury-containing preservative used in multidose vials of the influenza vaccine, may be unsafe, there is no scientific evidence that thimerosal-containing vaccines cause health or developmental problems in children born to women who received vaccines with thimerosal during pregnancy. Although thimerosal-free formulations of the influenza vaccine are available, the CDC’s Advisory Committee on Immunization Practices does not indicate a preference for thimerosal-containing or thimerosal-free vaccines for pregnant women (ACOG, 2018).  

H1N1 (Swine Flu)

According to the CDC, H1N1 (swine flu) is an influenza virus that was first detected in people in the U.S. in April 2009.  It spreads from person-to-person in much the same way that regular seasonal influenza viruses spread (i.e., through coughing or sneezing by people with influenza).  This virus was originally referred to as "swine flu" because laboratory testing showed that many of the genes in this new virus were very similar to influenza viruses that normally occur in pigs (swine) in North America.  However, studies have shown that this new virus is very different from what normally circulates in North American pigs.  It has two genes from flu viruses that normally circulate in pigs in Europe and Asia as well as genes from bird (avian) flu and human influenza strains.  It is referred to as a "quadruple reassortant" virus.  Symptoms are similar to seasonal influenza (e.g., fever and chills, cough, sore throat, muscle aches, headache, and extreme fatigue).  The CDC, however, reported that there is little 2009 H1N1 virus currently circulating in the U.S. and the Department of Health and Human Services has declared the end of the H1N1 influenza public health emergency as of June 23, 2010. With 2009 H1N1, aprroximately 90 % of estimated hospitalizations and 87 % of estimated deaths from April 2009 through January 16, 2010 occurred in people younger than age 65 years.  In contrast, with seasonal influenza, about 60 % of seasonal flu-related hospitalizations and 90 % of flu-related deaths occur in people aged 65 years and older.  These data confirm that the 2009 H1N1 impacted younger adults and children more than older adults compared to seasonal flu.  However, people in all age groups can develop severe illness from either seasonal flu or from 2009 H1N1.

Population-Specific

Nichol and colleagues (2007) examined the effectiveness of influenza vaccine in seniors over the long-term.  Data were pooled from 18 cohorts of community-dwelling elderly members of 1 U.S. health maintenance organization (HMO) for 1990 to 1991 through 1999 to 2000 and of 2 other HMOs for 1996 to 1997 through 1999 to 2000.  Logistic regression was used to estimate the effectiveness of the vaccine for the prevention of hospitalization for pneumonia or influenza and death after adjustment for important co-variates.  Additional analyses explored for evidence of bias and the potential effect of residual confounding.  There were 713,872 person-seasons of observation.  Most high-risk medical conditions that were measured were more prevalent among vaccinated than among unvaccinated persons.  Vaccination was associated with a 27 % reduction in the risk of hospitalization for pneumonia or influenza (adjusted odds ratio, 0.73; 95 % confidence interval [CI]: 0.68 to 0.77) and a 48 % reduction in the risk of death (adjusted odds ratio, 0.52; 95 % CI: 0.50 to 0.55).  Estimates were generally stable across age and risk subgroups.  In the sensitivity analyses, these researchers modeled the effect of a hypothetical unmeasured confounder that would have caused over-estimation of vaccine effectiveness in the main analysis; vaccination was still associated with statistically significant -- though lower -- reductions in the risks of both hospitalization and death.  The authors concluded that during 10 seasons, influenza vaccination was associated with significant reductions in the risk of hospitalization for pneumonia or influenza and in the risk of death among community-dwelling elderly persons.  They noted that vaccine delivery to this high-priority group should be improved.

In an editorial that accompanied the afore-mentioned study, Treanor (2007) stated that these findings support the current policy of vaccinating the elderly but also demonstrate that the inactivated influenza vaccine is by itself a relatively mediocre means for controlling flu in this population.  Until more immunogenic vaccines are developed, routine vaccination of children as well as health care workers could limit transmission and play an important role in controlling the development of influenza in the elderly.

Maternal influenza immunization is a strategy with substantial benefits for both mothers and infants.  Zaman et al (2008) evaluated the clinical effectiveness of inactivated influenza vaccine administered during pregnancy in Bangladesh.  In this randomized study, a total of 340 mothers were assigned to receive either inactivated influenza vaccine (influenza-vaccine group) or the 23-valent pneumococcal polysaccharide vaccine (control group).  Mothers were interviewed weekly to assess illnesses until 24 weeks after birth.  Subjects with febrile respiratory illness were assessed clinically, and ill infants were tested for influenza antigens.  These researchers estimated the incidence of illness, incidence rate ratios, and vaccine effectiveness.  Mothers and infants were observed from August 2004 through December 2005.  Among infants of mothers who received influenza vaccine, there were fewer cases of laboratory-confirmed influenza than among infants in the control group (6 cases and 16 cases, respectively), with a vaccine effectiveness of 63 % (95 % CI: 5 to 85).  Respiratory illness with fever occurred in 110 infants in the influenza-vaccine group and 153 infants in the control group, with a vaccine effectiveness of 29 % (95 % CI: 7 to 46).  Among the mothers, there was a reduction in the rate of respiratory illness with fever of 36 % (95 % CI: 4 to 57).  The authors concluded that inactivated influenza vaccine reduced proven influenza illness by 63 % in infants up to 6 months of age and averted about one-third of all febrile respiratory illnesses in mothers and young infants. 

Guidelines for preventing infections in hematopoietic cell transplant (HCT) recipients by the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, European Group for Blood and Marrow Transplantation, American Society for Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease, and the CDC (Ljungman et al, 2009) indicated that intranasal influenza vaccine (live) should not be given to HCT recipients since an effective, inactivated alternative exist.

Available evidence shows that two doses of influenza vaccine does not improve antibody reponse in persons with hematologic malignancies.  In a randomized controlled study (n = 70), Ljungman and associates (2005) examined if 2 doses of influenza vaccine were more effective than one to elicit an immune response in patients with hematological malignancies.  These investigators found that responses were not improved by 2 doses compared with 1 (influenza A virus serotypes H1/N1 18 % versus 22 % and H3/N2 26 % versus 14 %; influenza B 25 % versus 22 %).  The results were similar in patients with ongoing and discontinued therapy.  Patients treated with monoclonal antibodies for lymphoma had very poor responses.  These researchers concluded that 2 doses of influenza vaccine do not improve the antibody response in patients with hematological malignancies.

Madhi et al (2014) conducted 2 double-blind, randomized, placebo-controlled trials of trivalent IIV (IIV3) in South Africa during 2011 in pregnant women infected with HIV and during 2011 and 2012 in pregnant women who were not infected.  The immunogenicity, safety, and efficacy of IIV3 in pregnant women and their infants were evaluated until 24 weeks after birth.  Immune responses were measured with a HAI assay, and influenza was diagnosed by means of reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays of respiratory samples.  The study cohorts included 2,116 pregnant women who were not infected with HIV and 194 pregnant women who were infected with HIV.  At 1 month after vaccination, sero-conversion rates and the proportion of participants with HAI titers of 1:40 or more were higher among IIV3 recipients than among placebo recipients in both cohorts.  Newborns of IIV3 recipients also had higher HAI titers than newborns of placebo recipients.  The attack rate for RT-PCR-confirmed influenza among both HIV-uninfected placebo recipients and their infants was 3.6 %.  The attack rates among HIV-uninfected IIV3 recipients and their infants were 1.8 % and 1.9 %, respectively, and the respective vaccine-efficacy rates were 50.4 % (95 % CI: 14.5 to 71.2) and 48.8 % (95 % CI: 11.6 to 70.4).  Among HIV-infected women, the attack rate for placebo recipients was 17.0 % and the rate for IIV3 recipients was 7.0 %; the vaccine-efficacy rate for these IIV3 recipients was 57.7 % (95 % CI: 0.2 to 82.1).  The authors concluded that influenza vaccine was immunogenic in HIV-uninfected and HIV-infected pregnant women and provided partial protection against confirmed influenza in both groups of women and in infants who were not exposed to HIV.

In a Cochrane review, Dharmaraj and Smyth (2014) evaluated the effectiveness of influenza vaccination for people with cystic fibrosis (CF).  These investigators searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and hand-searching of relevant journals and abstract books of conference proceedings.  They also contacted the companies which market the influenza vaccines used in the trials to obtain further information about RCTs.  Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register: July 8, 2013.  All randomized and quasi-randomized trials (published or unpublished) comparing any influenza vaccine with a placebo or with another type of influenza vaccine were selected for analysis.  Two authors independently assessed study quality and extracted data.  Additional information was obtained by contacting the investigators when it was indicated.  A total of 4 studies enrolling a total of 179 participants with CF (143 (80 %) were children aged 1 to 16 years) were included in this review.  There was no study comparing a vaccine to a placebo or a whole virus vaccine to a subunit or split virus vaccine.  Two studies compared an intra-nasal applied live vaccine to an intra-muscular inactivated vaccine and the other 2 studies compared a split virus to a subunit vaccine and a virosome to a subunit vaccine (all intra-muscular).  The incidence of all reported adverse events was high depending on the type of influenza vaccine.  The total adverse event rate ranged from 48 out of 201 participants (24 %) for the intra-nasal live vaccine to 13 out of 30 participants (43 %) for the split virus vaccine.  With the limitation of a statistical low power there was no significant difference between the study vaccinations.  None of the events was severe.  All study influenza vaccinations generated a satisfactory serological antibody response.  No study reported other clinically important benefits.  The authors concluded that there is currently no evidence from randomized studies that influenza vaccine given to people with CF is of benefit to them.  They stated that there remains a need for a well-constructed clinical study, that assesses the effectiveness of influenza vaccination on important clinical outcome measures.

Remschmidt et al (2015) noted that patients with diabetes are at increased risk of severe influenza disease; influenza vaccination for these patients is therefore recommended by the World Health Organization (WHO) and several National Immunization Technical Advisory Groups.  However, no systematic review has evaluated the effects of influenza vaccines for patients with diabetes.  These researchers conducted a systematic review and meta-analysis by searching Medline, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception until November 2014.  They included all types of studies reporting on the efficacy, effectiveness, and/or safety of influenza vaccination in patients with type 1 and type 2 diabetes mellitus of all ages.  They used the Newcastle-Ottawa scale to assess risk of bias in observational studies.  Residual confounding was addressed by comparing estimates of vaccine effectiveness (VE) during influenza seasons to those obtained during off-seasons.  Quality of the evidence for each outcome was assessed using the GRADE methodology.  Following review of 1,444 articles, 11 observational studies with a total of 170,924 participants were included.  In diabetic patients of working-age (18 to 64 years), influenza vaccination prevented all-cause hospitalization with a pooled VE of 58 % (95 % CI: 6 to 81 %) and hospitalization due to influenza or pneumonia (VE 43 %; 95 % CI: 28 to 54 %), whereas no effects on all-cause mortality and influenza-like illness (ILI) were observed.  In the elderly (65+), influenza vaccination prevented all-cause mortality (VE 38 %; 95 % CI: 32 to 43 %), all-cause hospitalization (VE 23 %; 95 % CI: 1 to 40 %), hospitalization due to influenza or pneumonia (VE 45 %; 95 % CI: 34 to 53 %), and ILI (VE 13 %; 95 % CI: 10 to 16 %).  However, significant off-season estimates for several outcomes indicated residual confounding, particularly in elderly patients.  Quality of the evidence was low to very low for all outcomes.  Laboratory-confirmed influenza infections were not reported.  The authors concluded that due to strong residual confounding in most of the identified studies, the available evidence is insufficient to determine the magnitude of benefit that diabetic people derive from seasonal influenza vaccination.  They stated that adequately powered RCTs or quasi-experimental studies using laboratory-confirmed influenza-specific outcomes are urgently needed.

In a Cochrane review, Norhayati et al (2015) stated that acute otitis media (AOM) is one of the most common infectious diseases in children.  It has been reported that 64 % of infants have an episode of AOM by the age of 6 months and 86 % by 1 year.  Although most cases of AOM are due to bacterial infection, it is commonly triggered by a viral infection.  In most children it is self-limiting, but it does carry a risk of complications.  Since antibiotic treatment increases the risk of antibiotic resistance, influenza vaccines might be an effective way of reducing this risk by preventing the development of AOM.  These investigators evaluated the effectiveness of influenza vaccine in reducing the occurrence of AOM in infants and children.  They searched CENTRAL (2014, Issue 6), MEDLINE (1946 to Week 1, July 2014), EMBASE (2010 to July 2014), CINAHL (1981 to July 2014), LILACS (1982 to July 2014), Web of Science (1955 to July 2014) and reference lists of articles to July 2014.  Randomized controlled trials comparing influenza vaccine with placebo or no treatment in infants and children aged younger than 6 years old.  These researchers included children of either sex and of any ethnicity, with or without a history of recurrent AOM.  Two review authors independently screened studies, assessed trial quality and extracted data.  They performed statistical analyses using the random-effects and fixed-effect models and expressed the results as RR, risk difference (RD) and number needed to treat to benefit (NNTB) for dichotomous outcomes, with 95 % CI.  These investigators included 10 trials (6 trials in high-income countries and 4 multi-center trials in high-, middle- and low-income countries) involving 16,707 children aged 6 months to 6 years.  Eight trials recruited participants from a healthcare setting; 9 trials (and all 5 trials that contributed to the primary outcome) declared funding from vaccine manufacturers.  Four trials reported adequate allocation concealment and 9 trials reported adequate blinding of participants and personnel.  Attrition was low for all trials included in the analysis.  The primary outcome showed a small reduction in at least 1 episode of AOM over at least 6 months of follow-up (5 trials, 4,736 participants: RR 0.80, 95 % CI: 0.67 to 0.96; RD -0.04, 95 % CI: -0.07 to -0.02; NNTB 25, 95 % CI: 15 to 50).  The subgroup analyses (i.e., number of courses, settings, seasons or types of vaccine administered) showed no differences.  There was a reduction in the use of antibiotics in vaccinated children (2 trials, 1,223 participants: RR 0.70, 95 % CI: 0.59 to 0.83; RD -0.15, 95 % CI: -0.30 to -0.00).  There was no significant difference in the utilization of health care for the 1 trial that provided sufficient information to be included.  The use of influenza vaccine resulted in a significant increase in fever (6 trials, 10,199 participants: RR 1.15, 95 % CI: 1.06 to 1.24; RD 0.02, 95 % CI: -0.00 to 0.05) and rhinorrhea (6 trials, 10,563 children: RR 1.17, 95 % CI: 1.07 to 1.29; RD 0.09, 95 % CI: 0.01 to 0.16) but no difference in pharyngitis.  No major adverse events were reported.  Compared to the protocol, the review included a subgroup analysis of AOM episodes by season, and changed the types of influenza vaccine from a secondary outcome to a subgroup analysis.  The authors concluded that influenza vaccine results in a small reduction in AOM.  The observed reduction with the use of antibiotics needs to be considered in the light of current recommended practices aimed at avoiding antibiotic overuse.  Safety data from these trials are limited.  They stated that the benefits may not justify the use of influenza vaccine without taking into account the vaccine efficacy in reducing influenza and safety data.  The quality of the evidence was high-to-moderate; additional research is needed.

Prevention of Cardiovascular Diseases (e.g., e Acute Myocardial Infarction)

There is evidence to suggest that influenza vaccination improves the clinical course of coronary artery disease (CAD) and reduces the frequency of coronary ischemic events. In a randomized, double-blind, placebo-controlled trial, Ciszewski et al (2008) assessed the effect of influenza vaccination on the coronary events in patients with confirmed CAD.  This study included 658 optimally treated CAD patients (477 men, mean age of 59.9 +/- 10.3 years).  A total of 325 patients received the influenza vaccine, and 333 patients received a placebo.  Median follow-up was 298 days (inter-quartile range of  263 to 317).  Primary end-point was cardiovascular death.  Its estimated 12-month cumulative event rate was 0.63 % in the vaccine versus 0.76 % in controls (HR 1.06; 95 % CI: 0.15 to 7.56, p = 0.95).  There were 2 secondary composite end-points:

1. the MACE (cardiovascular death, myocardial infarction, coronary re-vascularization) tended to occur less frequently in the vaccine group versus placebo with the event rate 3.00 % and 5.87 %, respectively (HR 0.54; 95 % CI: 0.24 to 1.21, p = 0.13),
2. coronary ischemic event (MACE or hospitalization for myocardial ischemia) estimated 12-month event rate was significantly lower in the vaccine group 6.02 % versus 9.97 % in controls (HR 0.54; 95 % CI: 0.29 to 0.99, p = 0.047). 

The authors concluded that in optimally treated CAD patients, influenza vaccination improves the clinical course of CAD and reduces the frequency of coronary ischemic events.  They stated that large-scale studies are needed to evaluate the effect of influenza vaccination on cardiovascular mortality.

A Cochrane review concluded that despite the significant effects noted in available randomized controlled clinical trials, that there are not enough data to evaluate the effect of influenza vaccination on coronary heart disease (Keller et al, 2008).

Barnes and associates (2015) stated that acute myocardial infarction (AMI) is the leading cause of death and disability globally. There is increasing evidence from observational studies that influenza infection is associated with AMI.  In patients with known coronary disease, influenza vaccination is associated with a lower risk of cardiovascular events.  However, the effect of influenza vaccination on incident AMI across the entire population is less well established.  In a systematic review of case-control studies, these investigators

1. estimated the association between influenza infection and AMI, and
2. estimated the association between influenza vaccination and AMI. 

Cases included those conducted with first-time AMI or any AMI cases.  Studies were appraised for quality and meta-analyses using random effects models for the influenza exposures of infection, and vaccination were conducted.  A total of 16 studies (8 on influenza vaccination, 10 on influenza infection and AMI) met the eligibility criteria, and were included in the review and meta-analysis.  Recent influenza infection, influenza-like illness or respiratory tract infection was significantly more likely in AMI cases, with a pooled odds ratio (OR) of 2.01 (95 % CI: 1.47 to 2.76).  Influenza vaccination was significantly associated with AMI, with a pooled OR of 0.71 (95 % CI: 0.56 to 0.91), equating to an estimated vaccine effectiveness of 29 % (95 % CI: 9 % to 44 %) against AMI.  The authors concluded that the findings of this meta-analysis of case-control studies found a significant association between recent respiratory infection and AMI.  The estimated vaccine effectiveness against AMI was comparable with the effectiveness of currently accepted therapies for secondary prevention of AMI from clinical trial data.  They stated that al large-scale RCT is needed to provide robust evidence of the protective effect of influenza vaccination on AMI, including as primary prevention.

In a Cochrane review, Clar and colleagues (2015) evaluated the potential benefits of influenza vaccination for primary and secondary prevention of cardiovascular diseases.  These investigators searched the following electronic databases on October 18, 2013: The Cochrane Library (including Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Economic Evaluation Database (EED) and Health Technology Assessment database (HTA)), Medline, Embase, Science Citation Index Expanded, Conference Proceedings Citation Index - Science and ongoing trials registers (www.controlled-trials.com/ and www.clinicaltrials.gov).  They examined reference lists of relevant primary studies and systematic reviews, and performed a limited PubMed search on February 20, 2015, just before publication.  Randomized controlled trials of influenza vaccination compared with placebo or no treatment in participants with or without cardiovascular diseases, assessing cardiovascular death or non-fatal cardiovascular events.  These researchers used standard methodological procedures as expected by the Cochrane Collaboration; they performed meta-analyses only for cardiovascular death, as other outcomes were reported too infrequently.  They expressed effect sizes as RRs and used random-effects models.  The authors included 8 trials of influenza vaccination compared with placebo or no vaccination, with 12,029 participants receiving at least 1 vaccination or control treatment.  They included 6 new studies (n = 11,251), in addition to the 2 included in the previous version of the review; 4 of these trials (n = 10,347) focused on prevention of influenza in the general or elderly population and reported cardiovascular outcomes among their safety analyses; 4 trials (n = 1,682) focused on prevention of cardiovascular events in patients with established coronary heart disease.  These populations were analyzed separately; follow-up continued between 42 days and 1 year; 5  RCTs showed deficits in at least 3 of the risk of bias criteria assessed.  When reported (7 studies), vaccination provided adequate immunogenicity or protection against influenza.  Cardiovascular mortality was reported by 4 secondary prevention trials and was significantly reduced by influenza vaccination overall (RR of 0.45, 95 % CI: 0.26 to 0.76; p value of 0.003) with no significant heterogeneity between studies, and by 3 trials reporting cardiovascular mortality as part of their safety analyses when the numbers of events were too small to permit conclusions.  In studies of patients with coronary heart disease, composite outcomes of cardiovascular events tended to be decreased with influenza vaccination compared with placebo.  Generally no significant difference was found between comparison groups regarding individual outcomes such as MI.  The authors concluded that in patients with cardiovascular disease, influenza vaccination may reduce cardiovascular mortality and combined cardiovascular events.  However, studies had some risk of bias, and results were not always consistent, so additional higher-quality evidence is needed to confirm these findings.  They stated that not enough evidence was available to establish whether influenza vaccination has a role to play in the primary prevention of cardiovascular diseases.

Table: CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
CPT codes covered if selection criteria are met:
90630	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use
90653	Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use
90654	Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use
90655	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use
90656	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90657	Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use
90658	Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use
90661	Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
90662	Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
90672	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
90673	Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90674	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
90682	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90685	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use
90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90687	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
90694	Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use [over age 65]
90756	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use
CPT codes not covered for indications listed in the CPB:
90660	Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use
90664	Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use
Other CPT codes related to the CPB:
87275	Infectious agent antigen detection by immunoflourescent technique; influenza B virus
87276	influenza A virus
87400	Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi quantitative, multiple step method; influenza A or B, each
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered
90461	each additional vaccine or toxoid component administered (list separately in addition to code for primary procedure)
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, intramuscular injections); one vaccine (single or combination vaccine/toxoid)
+ 90472	each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
90473	Immunization administration by intranasal or oral route: one vaccine (single or combination vaccine/toxoid)
+ 90474	each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
90666	Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use
90667	Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use
90668	Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use
HCPCS codes covered if selection criteria are met:
G0008	Administration of influenza virus vaccine
J3530	Nasal vaccine inhalation
Q2034	Influenza virus vaccine, split virus, for intramuscular use (agriflu)
Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Afluria)
Q2036	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Flulaval)
Q2037	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluvirin)
Q2038	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone) [also covered for Fluzone High-Dose for member's age 65 years of age or older when influenza immunization is recommended]
Q2039	Influenza virus vaccine, split virus, not otherwise specified
Other HCPCS codes related to the CPB:
G0310	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time (this code is used for Medicaid billing purposes)
G0311	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time (this code is used for Medicaid billing purposes)
G0312	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time (this code is used for Medicaid billing purposes)
G0313	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time (this code is used for Medicaid billing purposes)
ICD-10 codes covered if selection criteria are met:
Z23	Encounter for immunization

The above policy is based on the following references: